• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by VP, Finance and PAO Nemec Sarah

    7/24/24 5:17:51 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Nemec Sarah

    (Last) (First) (Middle)
    900 CHESAPEAKE DRIVE

    (Street)
    REDWOOD CITY CA 94063

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bolt Biotherapeutics, Inc. [ BOLT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP, Finance and PAO
    3. Date of Earliest Transaction (Month/Day/Year)
    07/23/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $0.7301 07/23/2024 A 50,000 (1) 07/22/2034 Common Stock 50,000 $0 50,000 D
    Stock Option (Right to Buy) $0.7301 07/23/2024 A 90,000 (2) 07/22/2034 Common Stock 90,000 $0 90,000 D
    Explanation of Responses:
    1. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.
    2. For so long as the Reporting Person continuously provides services to the Issuer this option will vest on July 15, 2025.
    /s/ William P. Quinn, Attorney-in-Fact 07/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BOLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BOLT

    DatePrice TargetRatingAnalyst
    1/6/2022$45.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2022Overweight → Equal-Weight
    Morgan Stanley
    11/10/2021$35.00 → $33.00Outperform
    SVB Leerink
    8/16/2021$34.00 → $35.00Outperform
    SVB Leerink
    More analyst ratings

    $BOLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

      Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

      5/8/25 8:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

      CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting. "We are encouraged by these early results from our next-generation Boltbody™ ISACs targeting CEA a

      4/30/25 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

      BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of BDC-3042 REDWOOD CITY, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treat

      4/25/25 1:00:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dupont Jakob

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 9:28:46 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Yonehiro Grant

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:41:01 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:40:30 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      11/14/24 4:19:06 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      2/14/24 4:57:08 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      2/14/24 4:00:25 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bolt Biotherapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously

      1/6/22 9:46:37 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight

      1/6/22 7:59:47 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Bolt Biotherapeutics with a new price target

      SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $35.00 previously

      11/10/21 6:28:31 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Bolt Biotherapeutics Inc.

      DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/25/25 3:48:22 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/16/25 5:22:57 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Bolt Biotherapeutics Inc.

      PRE 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/15/25 7:12:43 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:40:30 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Quinn William P. bought $2,835 worth of shares (5,000 units at $0.57) (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:35:34 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quinn William P. bought $11,241 worth of shares (11,829 units at $0.95), increasing direct ownership by 48% to 36,272 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      12/13/23 1:40:19 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Bolt Biotherapeutics Announces Changes to its Board of Directors

      REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja

      9/4/24 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira Appoints Frank D. Lee as Chief Executive Officer

      -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r

      12/21/23 7:30:00 AM ET
      $BOLT
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

      REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact

      12/14/22 4:43:15 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Financials

    Live finance-specific insights

    See more
    • Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

      Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

      5/8/25 8:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

      Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic

      5/14/24 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

      Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, the company's lead immune-stimulat

      12/6/21 6:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care